◆ NeutralDERM
Are Options Traders Betting on a Big Move in Journey Medical Stock?
Zacks Investment Research·
Journey Medical (DERM) is experiencing elevated implied volatility in its September 2026 $50 call options, suggesting traders expect significant price movement. However, the company holds a Zacks Rank #4 (Sell) rating, with analysts downgrading estimates over the past 60 days, reducing consensus earnings from 9 cents to 2 cents per share. The high volatility may present opportunities for premium-selling strategies rather than bullish positioning.
Read Full Article at Zacks Investment Research →